Alto Neuroscience (ANRO) · ALTO-300
Later window · A neutral label from comparing the two stated windows. It says nothing about the program’s results.
Before
Stated timing: mid-2026
We expect to report topline data from this trial in mid-2026.
· filed · SEC filing
After
Stated timing: 1H 2027
1H 2027 — ALTO-300 Phase 2b MDD trial topline data
SEC original · filed · SEC filing
Data as of . Both sentences are quoted from the SEC filings linked above and matched to them.
Source: ORION, orionbiotechai.com/changes/ANRO-alto-300-2026-08-12, data as of Oct 13, 2026
https://www.orionbiotechai.com/changes/ANRO-alto-300-2026-08-12
Alto Neuroscience (ANRO) pipeline and stated timing · Calendar · Companies A–Z
A Form 10-K is a company’s annual report to the SEC, with audited financial statements.